Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 15/20 | 0.81 |
| ▸ | KDR | P35968 | 13/20 | 0.81 |
| ▸ | KIT | P10721 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.73 |
| ▸ | AXL | P30530 | 1/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.70 |
| ▸ | MET | P08581 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27082957 | 0.91 | PDGFRA (0.82) | PDGFRAKDRKITFLT3AURKB | |
| SCHEMBL27081475 | 0.91 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL29973354 | 0.91 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL30918281 | 0.91 | PDGFRA (0.82) | PDGFRAKDRKITFLT3AURKB | |
| SCHEMBL7490931 | 0.90 | PDGFRA (1.00) | PDGFRAKDRKITFGFR2 | |
| SCHEMBL6228087 | 0.89 | PDGFRA (0.79) | PDGFRAKDRKITFLT3AURKB | |
| SCHEMBL5824534 | 0.89 | PDGFRA (0.79) | PDGFRAKDRKITFLT3AURKB | |
| SCHEMBL3931065 | 0.89 | PDGFRA (1.00) | PDGFRAKDRFGFR2 | |
| SCHEMBL8070553 | 0.89 | PDGFRA (0.94) | PDGFRAKDRKIT | |
| SCHEMBL6227250 | 0.88 | PDGFRA (0.85) | PDGFRAKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| EP-3896059-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | KIT, MAP3K7, ABL1 | PDGFRA 747/4885KDR 357/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.